About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

NCT05181995·37 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Aptinyx

With

Worldwide Clinical Trials

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

PTSD (DSM-5 criteria)
Stable allowed medications with no planned changes from 30 days prior to screening through study participation
Willing to use highly effective birth control
Willing to comply with protocol visits and procedures

You may not be if

Moderate to severe traumatic brain injury
Other psychiatric disorders (based on SCID-5-CT) or neurodegenerative disorders
Substance use disorder or alcohol use disorder within 6 months prior to screening
Psychotherapy or cognitive based therapy within 30 days prior to screening
Use of investigational drug within 30 days prior to screening
Prior participation in study of NYX-783, NYX-2925 or NYX-458.

The record

StatusTerminated

PhasePhase 2–3

Taking part121

StartedDec 2021

UpdatedApr 7, 2023

Conditions

Where37

Aptinyx Clinical Site
Tuscaloosa, Alabama, United States
Aptinyx Clinical Site
Phoenix, Arizona, United States
Aptinyx Clinical Site
Bentonville, Arkansas, United States